Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on Celecoxib-induced apoptosis

Biochemical Pharmacology

Volumn 79, Issue 1, 2010, Pages 10-20

  Rudner, Justine ^a   Elsaesser, Simon Johannes ^a   Müller, Arndt Christian ^a   Belka, Claus ^a,b   Jendrossek, Verena ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Apoptosis; Bcl 2; Bcl xL; Cancer; Celecoxib; Mcl 1; Noxa

Indexed keywords

BETA ACTIN; CASPASE 3; CELECOXIB; CYCLOOXYGENASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; TUMOR CELL;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-X PROTEIN; DRUG DELIVERY SYSTEMS; HUMANS; JURKAT CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; SULFONAMIDES;

EID: 70350199628     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.07.021     Document Type: Article

References (51)

1. Belka C., Rudner J., Wesselborg S., Stepczynska A., Marini P., Lepple-Wienhues A., et al. Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis. Oncogene 19 (2000) 1181-1190
2. Habermehl D., Kammerer B., Handrick R., Eldh T., Gruber C., Cordes N., et al. Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer 6 (2006) 14
3. Weinmann M., Jendrossek V., Handrick R., Guner D., Goecke B., and Belka C. Molecular ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial death pathway in a FADD/caspase-8 independent manner. Oncogene 23 (2004) 3757-3769
4. You H., Pellegrini M., Tsuchihara K., Yamamoto K., Hacker G., Erlacher M., et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 203 (2006) 1657-1663
5. Adams J.M., and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26 (2007) 1324-1337
6. Certo M., Del Gaizo Moore V., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9 (2006) 351-365
7. Youle R.J., and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9 (2008) 47-59
8. Ruffolo S.C., and Shore G.C. BCL-2 selectively interacts with the BID-induced open conformer of BAK, inhibiting BAK auto-oligomerization. J Biol Chem 278 (2003) 25039-25045
9. Bouillet P., Huang D.C., O'Reilly L.A., Puthalakath H., O'Connor L., Cory S., et al. The role of the pro-apoptotic Bcl-2 family member bim in physiological cell death. Ann N Y Acad Sci 926 (2000) 83-89
10. Galonek H.L., and Hardwick J.M. Upgrading the BCL-2 network. Nat Cell Biol 8 (2006) 1317-1319
11. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., and Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 (2002) 183-192
12. Wei M.C., Lindsten T., Mootha V.K., Weiler S., Gross A., Ashiya M., et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 14 (2000) 2060-2071
13. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17 (2005) 393-403
14. Zha S., Yegnasubramanian V., Nelson W.G., Isaacs W.B., and De Marzo A.M. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215 (2004) 1-20
15. Uchida K. A lipid-derived endogenous inducer of COX-2: a bridge between inflammation and oxidative stress. Mol Cells 25 (2008) 347-351
16. Grosch S., Tegeder I., Niederberger E., Brautigam L., and Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Faseb J 15 (2001) 2742-2744
17. Muller A.C., Handrick R., Elsaesser S.J., Rudner J., Henke G., Ganswindt U., et al. Importance of Bak for celecoxib-induced apoptosis. Biochem Pharmacol 76 (2008) 1082-1096
18. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94 (2002) 585-591
19. Waskewich C., Blumenthal R.D., Li H., Stein R., Goldenberg D.M., and Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62 (2002) 2029-2033
20. Ding H., Han C., Zhu J., Chen C.S., and D'Ambrosio S.M. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 113 (2005) 803-810
21. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., and Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275 (2000) 11397-11403
22. Jendrossek V., Handrick R., and Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. Faseb J 17 (2003) 1547-1549
23. Johnson A.J., Smith L.L., Zhu J., Heerema N.A., Jefferson S., Mone A., et al. A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood 105 (2005) 2504-2509
24. Rudner J., Lepple-Wienhues A., Budach W., Berschauer J., Friedrich B., Wesselborg S., et al. Wild-type, mitochondrial and ER-restricted Bcl-2 inhibit DNA damage-induced apoptosis but do not affect death receptor-induced apoptosis. J Cell Sci 114 (2001) 4161-4172
25. Han J., Goldstein L.A., Gastman B.R., and Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 281 (2006) 10153-10163
26. Dai H., Meng X.W., Lee S.H., Schneider P.A., and Kaufmann S.H. Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis. J Biol Chem 284 (2009) 18311-18322
27. Sinha-Datta U., Taylor J.M., Brown M., and Nicot C. Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt. Apoptosis 13 (2008) 33-40
28. Alves N.L., Derks I.A., Berk E., Spijker R., van Lier R.A., and Eldering E. The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. Immunity 24 (2006) 703-716
29. Gomez-Bougie P., Wuilleme-Toumi S., Menoret E., Trichet V., Robillard N., Philippe M., et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67 (2007) 5418-5424
30. Hallaert D.Y., Spijker R., Jak M., Derks I.A., Alves N.L., Wensveen F.M., et al. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Differ 14 (2007) 1958-1967
31. Inoue S., Walewska R., Dyer M.J., and Cohen G.M. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 22 (2008) 819-825
32. Mei Y., Xie C., Xie W., Tian X., Li M., and Wu M. Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis. Neoplasia 9 (2007) 871-881
33. Morales A.A., Gutman D., Lee K.P., and Boise L.H. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 111 (2008) 5152-5162
34. Czabotar P.E., Lee E.F., van Delft M.F., Day C.L., Smith B.J., Huang D.C., et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A 104 (2007) 6217-6222
35. Warr M.R., Acoca S., Liu Z., Germain M., Watson M., Blanchette M., et al. BH3-ligand regulates access of MCL-1 to its E3 ligase. FEBS Lett 579 (2005) 5603-5608
36. Panka D.J., Cho D.C., Atkins M.B., and Mier J.W. GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem 283 (2008) 726-732
37. Willis S.N., Chen L., Dewson G., Wei A., Naik E., Fletcher J.I., et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19 (2005) 1294-1305
38. Sattler M., Liang H., Nettesheim D., Meadows R.P., Harlan J.E., Eberstadt M., et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275 (1997) 983-986
39. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315 (2007) 856-859
40. Zhai D., Jin C., Huang Z., Satterthwait A.C., and Reed J.C. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem 283 (2008) 9580-9586
41. Kim H., Rafiuddin-Shah M., Tu H.C., Jeffers J.R., Zambetti G.P., Hsieh J.J., et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8 (2006) 1348-1358
42. Konopleva M., Watt J., Contractor R., Tsao T., Harris D., Estrov Z., et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 68 (2008) 3413-3420
43. Huang S., and Sinicrope F.A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 68 (2008) 2944-2951
44. Kang M.H., Wan Z., Kang Y.H., Sposto R., and Reynolds C.P. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 100 (2008) 580-595
45. Kuroda J., Kimura S., Andreeff M., Ashihara E., Kamitsuji Y., Yokota A., et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 140 (2008) 181-190
46. Paoluzzi L., Gonen M., Bhagat G., Furman R.R., Gardner J.R., Scotto L., et al. The BH3-only mimetic ABT-737 synergizes the anti-neoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112 (2008) 2906-2916
47. Witham J., Valenti M.R., De-Haven-Brandon A.K., Vidot S., Eccles S.A., Kaye S.B., et al. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 13 (2007) 7191-7198
48. Zhang W., Konopleva M., Ruvolo V.R., McQueen T., Evans R.L., Bornmann W.G., et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 22 (2008) 808-818
49. Wei S.H., Dong K., Lin F., Wang X., Li B., Shen J.J., et al. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol (2008)
50. Wolter K.G., Verhaegen M., Fernandez Y., Nikolovska-Coleska Z., Riblett M., de la Vega C.M., et al. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 14 (2007) 1605-1616
51. Willis S.N., and Adams J.M. Life in the balance: How BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17 (2005) 617-625